Waldenstrom Macroglobulinemia clinical trials at UC Irvine

• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

  open to eligible people ages 18 years and up

  This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.

  Orange, California and other locations

Last updated: August 2019